Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Esbriet - withdrawal of application for variation to marketing authorisation

Esbriet - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

pirfenidone
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Esbriet
  • More information on Esbriet

Overview

Roche Registration GmbH withdrew its application for the use of Esbriet in the treatment of patients with unclassifiable interstitial lung disease.

The company withdrew the application on 19 May 2021.

Esbriet is a medicine used to treat adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath. ‘Idiopathic’ means that the cause of the disease is unknown.

Esbriet has been authorised in the EU since February 2011.

It contains the active substance pirfenidone and is available as capsules and tablets to be taken by mouth.

The company applied to extend the use of Esbriet to treat patients with unclassifiable interstitial lung disease. Interstitial lung disease (ILD) is a group of diseases that cause scarring in the lungs. In around 10% of patients, the disease has characteristics that do not allow it to be classified as a specific subset of ILD and is therefore referred to as unclassifiable ILD (UILD).

The mechanism of action of pirfenidone, the active substance in Esbriet, is not fully understood but it has been shown to reduce the production of fibroblasts and other substances involved in the formation of fibrous (scar) tissue during the body’s tissue repair process, thereby slowing down the progression of the disease in IPF patients.

In unclassifiable interstitial lung disease, Esbriet is expected to work in the same way as it does in its existing indication.

The company presented the results of a main study involving 253 patients with UILD who were given either Esbriet or placebo (a dummy treatment). The main measure of effectiveness was the change in the functioning of the patients’ lungs after 24 weeks of treatment, measured by their ‘forced vital capacity’ (FVC). FVC is the maximum amount of air the patient can breathe out forcefully after taking in a deep breath, which decreases as the condition gets worse.

The application was withdrawn after the European Medicines Agency had evaluated the initial information from the company and had prepared questions for the company. The company had not responded to the questions at the time of the withdrawal.

Based on the review of the available information, at the time of the withdrawal, the Agency had some concerns and its provisional opinion was that Esbriet could not have been authorised for the treatment of UILD. In particular, the Agency had concerns about the robustness of the data and the duration of the main study. The Agency was also not in agreement with the wording of the proposed indication.

Therefore, at the time of the withdrawal, the Agency’s opinion was that the benefits of Esbriet in the treatment of UILD did not outweigh its risks.

In its Withdrawal letter: Esbriet (II-69) notifying the Agency of the withdrawal of application, the company stated that its decision was based on EMA’s requirement for further justification and data on the use of Esbriet in the proposed indication.

The company informed the Agency that there are no consequences for patients in clinical trials using Esbriet.

If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

There are no consequences on the use of Esbriet in the treatment of IPF.

Questions and answers on the withdrawal of application to change the marketing authorisation for Esbriet (pirfenidone) (II-69)

Reference Number: EMA/354062/2021

English (EN) (123 KB - PDF)

First published: 25/06/2021
View
Other languages (22)

български (BG) (117.34 KB - PDF)

First published: 25/06/2021
View

español (ES) (94.17 KB - PDF)

First published: 25/06/2021
View

čeština (CS) (111.68 KB - PDF)

First published: 25/06/2021
View

dansk (DA) (93.99 KB - PDF)

First published: 25/06/2021
View

Deutsch (DE) (94.55 KB - PDF)

First published: 25/06/2021
View

eesti keel (ET) (93.68 KB - PDF)

First published: 25/06/2021
View

ελληνικά (EL) (117.97 KB - PDF)

First published: 25/06/2021
View

français (FR) (96.69 KB - PDF)

First published: 25/06/2021
View

hrvatski (HR) (111.32 KB - PDF)

First published: 25/06/2021
View

italiano (IT) (95.52 KB - PDF)

First published: 25/06/2021
View

latviešu valoda (LV) (116.16 KB - PDF)

First published: 25/06/2021
View

lietuvių kalba (LT) (113.9 KB - PDF)

First published: 25/06/2021
View

magyar (HU) (109.66 KB - PDF)

First published: 25/06/2021
View

Malti (MT) (114.63 KB - PDF)

First published: 25/06/2021
View

Nederlands (NL) (96.54 KB - PDF)

First published: 25/06/2021
View

polski (PL) (114.88 KB - PDF)

First published: 25/06/2021
View

português (PT) (95.5 KB - PDF)

First published: 25/06/2021
View

română (RO) (111.77 KB - PDF)

First published: 25/06/2021
View

slovenčina (SK) (112.04 KB - PDF)

First published: 25/06/2021
View

slovenščina (SL) (108.56 KB - PDF)

First published: 25/06/2021
View

Suomi (FI) (93.84 KB - PDF)

First published: 25/06/2021
View

svenska (SV) (95.17 KB - PDF)

First published: 25/06/2021
View

Key facts

Name of medicine
Esbriet
EMA product number
EMEA/H/C/002154
Active substance
Pirfenidone
International non-proprietary name (INN) or common name
pirfenidone
Therapeutic area (MeSH)
  • Idiopathic Pulmonary Fibrosis
  • Lung Diseases
  • Respiratory Tract Diseases
Anatomical therapeutical chemical (ATC) code
L04AX05
Marketing authorisation holder
Roche Registration GmbH
Date of issue of marketing authorisation valid throughout the European Union
27/02/2011
Date of withdrawal
19/05/2021

Documents

Withdrawal letter: Esbriet (II-69)

English (EN) (11.73 KB - PDF)

First published: 25/06/2021
View

Withdrawal assessment report for Esbriet (II-69)

AdoptedReference Number: EMA/286537/2021

English (EN) (4.91 MB - PDF)

First published: 25/06/2021
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Esbriet

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023
24/02/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021
25/06/2021

More information on Esbriet

  • Esbriet
This page was last updated on 25/06/2021

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union